The Goldman Sachs Group assumed coverage on shares of Entrada Therapeutics (NASDAQ:TRDA) in a research note released on Tuesday, Price Targets.com reports. The brokerage issued a neutral rating and a $29.00 price target on the stock.
The Goldman Sachs Group assumed coverage on shares of Entrada Therapeutics (NASDAQ:TRDA) in a research note released on Tuesday, Price Targets.com reports. The brokerage issued a neutral rating and a $29.00 price target on the stock.